Kuhn W, Müller T
Department of Neurology, St. Josef-Hospital, Bochum, Federal Republic of Germany.
J Neural Transm Suppl. 1996;48:85-93. doi: 10.1007/978-3-7091-7494-4_8.
This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson's disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette's syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer's disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.
本文综述了司来吉兰（Deprenyl）用于除帕金森病之外的各种神经和精神疾病的临床研究结果。在三项不同试验中，司来吉兰以至少20毫克/天的剂量用于发作性睡病，以及在一项针对抽动秽语综合征（包括注意力多动障碍）的研究中，平均剂量为8.1毫克/天，均观察到了有前景的结果。关于阿尔茨海默病的研究结果存在争议。一方面，多位作者发现认知功能有显著改善。另一方面，在最近一项研究中，未观察到对疾病进展有影响。对于抑郁症，似乎需要30至60毫克/天的更高剂量司来吉兰才能进行有效治疗。在肌萎缩侧索硬化症和迟发性运动障碍中未发现阳性结果。
